Tatalaksana Vitiligo
DOI:
https://doi.org/10.55175/cdk.v46i11.404Keywords:
depigmentasi kulit, disfungsi kulit, vitiligoAbstract
Vitiligo merupakan kelainan depigmentasi kulit yang ditandai dengan lesi klinis makula atau plak depigmentasi berbatas tegas, diperkirakan karena faktor imun, genetik, disfungsi sekunder dan kehilangan melanosit. Terdapat 3 tipe vitiligo : vitiligo segmental (VS), vitiligo non-segmental (NSV) dan vitiligo campuran. Penatalaksanaan vitiligo secara medikamentosa dan non – medikamentosa.
Vitiligo is a skin disease characterized by a clinically well-defined macular or depigmented plaque; may be due to immune factors, genetics, secondary dysfunction and loss of melanocytes. There are 3 types of vitiligo: segmental vitiligo (VS), non-segmental vitiligo (NSV) and mixed vitiligo. Management of vitiligo is generally divided into medical treatment and procedural treatments.
Downloads
References
Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Vitiligo. Lancet. 2015;386 (9988):74–84.
What is vitiligo, fast facts: An easy-to-read series of publications for the public, U.S. Department of Health and Human Services, Public Health Service, November 2010.
Tortora GJ, Derrickson B. Principles of anatomy and physiology. 11th ed. Wiley International; 2013. p.150-1.
Boissy RE, Spritz RA. Frontiers and controversies in the pathobiology of vitiligo: Separating the wheat from the chaff. Exp Dermatol. 2009;18:583
Spritz RA. The genetics of generalized vitiligo. Curr Dir Autoimmun 2008;10: 244
Gauthier Y, Cario Andre M, Taïeb A. A critical appraisal of vitiligo etiologic theories. Is melanocyte loss a melanocytorrhagy? Pigment Cell Res. 2003; 16:322
Orecchia GE. Neural pathogenesis. In: Hann S-K, Nordlund JJ, eds. Vitiligo. London: Blackwell Sci; 2000.
Dell’Anna ML, Picardo M. A review and a new hypothesis for non-immunological pathogenetic mechanisms in vitiligo. Pigment Cell Res. 2006;19:406
Lerner AB, Nordlund JJ: Vitiligo: The loss of pigment in skin, hair and eyes. J Dermatol. 1978;5:1
Alkhateeb A, Fain PR, Thody A, Bennett DC, Spritz RA. Epidemiology of vitiligo and associated autoimmune diseases in Caucasian probands and their families. Pigment Cell Res, 2003;16:208
Jin Y, Birlea SA, Fain PR, Gowan K, Riccardi SL, Holland PJ, et al. Variant of TYR and autoimmunity susceptibility loci in generalized vitiligo. New Engl J Med. 2010;362(18):1686-97
Happle R. Loss of heterozygosity in human skin. J Am Acad Dermatol. 1999;41:143
Taïeb A, Morice-Picard F, Jouary T, Ezzedine K, Cario-André M, Gauthier Y. Segmental vitiligo as the possible expression of cutaneous somatic mosaicism: Implications for common non-segmental vitiligo. Pigment Cell Melanoma Res. 2008;21:646
Ongenae K, Van Geel N, Naeyaert JM. Evidence for an autoimmune pathogenesis of vitiligo. Pigment Cell Res. 2003;16:90
Kemp EH, Gavalas NG, Gawkrodger DJ, Weetman AP. Autoantibody response to melanocytes in the depigmenting skin disease vitiligo. Autoimmun Rev 2007;6:138
Norris DA, Kissinger RM, Naughton GM, Bystryn JC. Evidence for immunologic mechanisms in human vitiligo: Patients’ sera induce damage to human melanocytes in vitro by complement-mediated damage and antibody - dependent cellular cytotoxicity. J Invest Dermatol. 1988;90:783.
Gilhar A, Zelickson B, Ulman Y, Etzioni A. In vivo destruction of melanocytes by the IgG fraction of serum from patients with vitiligo. J Invest Dermatol. 1995;105:683
Oyarbide-Valencia K, van den Boorn JG, Denman CJ, Li M, Carlson JM, Hernandez C, et al. Therapeutic implications of autoimmune vitiligo T cells. Autoimmune Rev. 2006;5:486
Manga P, Sheyn D, Yang F, Sarangarajan R, Boissy RE. A role for tyrosinase related - protein 1 in 4-tert-butylphenol-induced toxicity in melanocytes. Implications for vitiligo. Am J Pathol. 2006;169:1652
Verheven J, Bonig H, Banning U, Shin DI, Mauz-Körholz C, Körholz D. Cooperation of IL-1 and IL-2 on T-cell activation in mononuclear cell cultures. Immunol Invest. 2001;30:289
Feliciani C, Gupta AK, Sauder DN. Keratinocytes and cytokine / growth factors. Crit Rev Oral Biol Med. 1996;7:300
Quaglino P, Marenco F, Osella-Abate S, Cappello N, Ortoncelli M, Salomone B, et al. Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: Results from a single - institution hospital-based observational cohort study. Ann Oncol. 2010;21:409
Prignano F, Pescitelli L, Becatti M, Di Gennaro P, Fiorillo C, Taddei N, et al. Ultrastructural and functional alterations of mitochondria in perilesional vitiligo skin. J Dermatol Sci. 2009;54:157
Dell’Anna ML, Ottaviani M, Bellei B, Albanesi V, Cossarizza A, Rossi L, et al. Membrane lipid defects are responsible for the generation of reactive oxygen species in peripheral blood mononuclear cells from vitiligo patients. J Cell Physiol. 2010;223:187
Esfandiarpour I, Ekhlasi A, Farajzadeh S, Shamsadini S. The efficacy of pimecrolimus 1% cream plus narrow-band ultraviolet B in the treatment of vitiligo: A doubleblind, placebo-controlled clinical trial. J Dermatolog Treat 2009;20: 14-18.
Njoo MD, Westerhof W, Lotti T, Hercogova J. Therapeutic guidelines for vitiligo. In: Dekker M. Vitiligo: Problems and solutions. New York; 2004. p: 235-52.
Koga M, Tango T. Clinical features and course of type A and type B vitiligo. Br J Dermatol. 1988;118:223
Song MS et al. Clinical study of vitiligo: comparative study of type A and type B vitiligo. Ann Dermatol 1994;6:22
Hann S-K, Nordlund JJ. Clinical features of generalized vitiligo, In: Vitiligo, edited by S-K Hann, JJ Nordlund. London, Blackwell Sci. 2000, p. 35.
Talia K. Vitiligo in children: A review of classification, hypotheses of pathogenesis and treatment. World J Pediatr. 2009; 4: 265-268
Le Poole IC, van den Wijngaard RM, Westerhof W, Dutrieux RP, Das PK. Presence or absence of melanocytes in vitiligo lesions: An immunohistochemical investigation. J Invest Dermatol 1993;100:816.
Roh M, Oh SH. Acquired hypopigmentation disorders other than vitiligo. Pubmed [Internet]. 2018. Available from: https://www.uptodate.com/contents/acquiredhypopigmentation-disorders-other-than-vitiligo
Ho N, Pope E, Weinstein M, Greenberg S, Webster C, Krafchik BR. A double-blind, randomized, placebo- controlled trial of topical tacrolimus 0•1% vs. clobetasol propionate 0•05% in childhood vitiligo. Br J Dermatol. 2011;165:626–32
Parsad D, Pandhi R, Dogra S, Kumar B. Clinical study of repigmentation patterns with di erent treatment modalities and their correlation with speed and stability of repigmentation in 352 vitiliginous patches. J Am Acad Dermatol. 2004;50:63
Lawrence ID. Tacrolimus (FK 506): Experience in dermatology. Dermatol Ther. 1998;5:74
Birlea SA, Costin GE, Norris DA. New insights on therapy with vitamin D analogs targeting the intracellular pathways that control repigmentation in human vitiligo. Med Res Rev. 2009;29:514
Kang HY, Choi YM Br J. FK 506 increases pigmentation and migration of human melanocytes. Br J Dermatol. 2006;155:1037
Taïeb A, Picardo M. Clinical practice. Vitiligo. N Engl J Med. 2009;360:160
Kanwar AJ, Mahajan R, Parsad D. Low-dose oral mini-pulse dexamethasone therapy in progressive unstable vitiligo. J Cutan Med Surg. 2013;17:259–68
Falabella R, Barona MI. Update on skin repigmentation therapies in vitiligo. Pigment Cell Melanoma Res. 2009;22:42
Lotti T, Berti S, Moretti S. Vitiligo therapy Expert Opin Pharmacother. 2009;10:2779
Westerhof W, Nieuweboer-Krobotova L. Treatment of vitiligo with UV-B radiation vs topical psoralen plus UV-A. Arch Dermatol. 1997;133:1525
Njoo MD, Bos JD, Westerhof W. Treatment of generalized vitiligo in children with narrow-band (TL-01) UVB radiation therapy. J Am Acad Dermatol. 2000;42:245
Anbar TS, Westerhof W, Abdel-Rahman AT, El-Khayyat MA. Evaluation of the effects of NB-UVB in both segmental and non-segmental vitiligo affecting body sites. Photodermatol Photoimmunol Photomed. 2006;22:157
Nicolaidou E, Antoniou C, Stratigos AJ, Stefanaki C, Katsambas AD. Efficacy predictors of response, and long-term follow-up in patients with vitiligo treated with narrowband UVB phototherapy. J Am Acad Dermatol. 2007;56:274
Halder RM, Chappell JL. Vitiligo update. Semin Cutan Med Surg. 2009;28:86
Kahn AM, Cohen MJ, Kaplan L, Highton A. Vitiligo: Treatment by dermabrasion and epithelial sheet grafting—A preliminary report. J Am Acad Dermatol. 1993;28:773
Laxmisha C, Thappa DM. Surgical Pearl: Surgical tape for dressing of epidermal grafts in lip vitiligo. J Am Acad Dermatol. 2005;53:498
Gupta S, Goel A, Kanwar AJ. Surgical management of lip vitiligo. In: Gupta BS, Olsson MJ, Kanwar AJ, Ortonne JP, eds. Surgical management of vitiligo. Singapore, Blackwell Publ.; 2006. p. 747
Hariharan V, Klarquist J, Reust MJ, Koshoffer A, McKee MD, Boissy RE, et al. Monobenzyl ether of hydroquinone and 4-tertiary butyl phenol activate markedly different physiological responses in melanocytes: Relevance to skin depigmentation. J Invest Dermatol. 130;211:2010
Wolff K, Goldsmith L, Katz S, Gilchrest B, Paller AS, Leffell D. Fitzpatrick's dermatology in general medicine. 8th ed. New York: McGraw-Hill; 2011
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2019 https://creativecommons.org/licenses/by-nc/4.0/
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
